Teva Pharmaceutical Industries Ltd. (TEVA)

12.88
0.14 1.08
NYSE : Health Technology
Prev Close 13.02
Open 13.02
Day Low/High 12.74 / 13.04
52 Wk Low/High 6.07 / 13.76
Volume 8.65M
Avg Volume 17.29M
Exchange NYSE
Shares Outstanding 1.10B
Market Cap 14.33B
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)
Cramer: We Need to Be Able to Predict a Clear Election Winner

Cramer: We Need to Be Able to Predict a Clear Election Winner

Without it, the uncertainty would be incredible between now and November.

Mylan Still Isn't Cheap

Mylan Still Isn't Cheap

The EpiPen controversy makes this stock a shot in the dark.

How to Play It When the FDA Slams Your Stock

How to Play It When the FDA Slams Your Stock

Here are three recent examples of how the patient can profit.

Cramer: The Answer to This Market: Part 1

Cramer: The Answer to This Market: Part 1

The leadership is quite stark.

Bret Jensen Reporting for Duty

Good morning, Bret Jensen here! It's good to be standing in for Doug Kass again on the daily diary as we begin a new trading week. Biotech -- my favorite subject -- should be a hot topic today after Pfizer appears to have outbid Sanofi for oncology ...

Allergan Stock Is 'Misunderstood'

Allergan Stock Is 'Misunderstood'

AAP portfolio managers Cramer and Mohr defend the drug company after it tops analysts' bottom-line expectations while missing top-line estimates.

Teva downgraded at Oppenheimer

Gilead and Teva: Off-the-Charts Cheap

Gilead and Teva: Off-the-Charts Cheap

Rarely do investors get to buy these types of quality businesses at such discounted prices.

Biogen Tie-Up Would Still Bring Premium, Analysts Say

Biogen Tie-Up Would Still Bring Premium, Analysts Say

Deal rumors are deflating, but a takeover bid could reward holdouts.

Mylan's Weakness Shouldn't Last, So Buy Now

Mylan's Weakness Shouldn't Last, So Buy Now

An investor should make good money on any turn in the drug maker's business or in investor sentiment.

Allergan Cures Its Ailing Chart

Allergan Cures Its Ailing Chart

The stock has broken free of tiresome resistance in a big way.

Synergy Pharma Offers Lots of Synergies

Synergy Pharma Offers Lots of Synergies

I expect Allergan or another player to bid for SGYP soon.

Teva downgraded at Goldman

Allergan Deal Should Give Teva Va-Va-Voom

Allergan Deal Should Give Teva Va-Va-Voom

The drug maker is a compelling buy and has 50% upside potential over the next 18 to 24 months.

My Takeaways and Observations

I made my second generational low call in seven years today. Peak Bonds. And a generational low in yields has possibly been reached. Peak Greed! Buyers live higher and sellers live lower in a marketplace dominated by machines and algos. Price moment...

Cramer: 10 Stocks That Need to Start Doing Better

Cramer: 10 Stocks That Need to Start Doing Better

They need to do something that makes them stand out as stocks you want to own, not avoid.

Morning Movers: TSLA, TEVA, GS, MSFT, DIS

Tesla shares sink on delivery miss while Goldman Sachs looks to curb spending within its asset-management division.

Allergan, Alphabet & L Brands Will Shine in Second Half

Allergan, Alphabet & L Brands Will Shine in Second Half

The economy's fundamentals, as well as corporate earnings growth, look better now than at the beginning of the year.

Here’s Why Shares of Allergan Are Higher on Tuesday

Here’s Why Shares of Allergan Are Higher on Tuesday

Allergan shares are up slightly following news that activist investor Carl Icahn recently acquired a 'large position' in the pharmaceutical company.

Cramer: There Are Some Bargains Out There

Allergan and retailers are just a couple of examples.

Carl Icahn's Position Boosts Confidence in Allergan's CEO

Carl Icahn's Position Boosts Confidence in Allergan's CEO

We expect an upward revision in AGN's valuation multiple after the generics deal with Teva.

Icahn, Chart, Valuation -- Allergan May Have It All

Icahn, Chart, Valuation -- Allergan May Have It All

Allergan's stock may start to realize the potential already seen by several Real Money analysts and contributors.

Endo Could Be the Next Activist Target in Generics

Endo Could Be the Next Activist Target in Generics

Problems with mesh products and high leverage might scare away a potential buyer. 

Teva Should Break Out of Droopy Drug Pack

Teva Should Break Out of Droopy Drug Pack

Despite an earnings beat and upbeat outlook, its stock has suffered with other drug makers.

Allergan's Results Were Exactly the Soft Catalyst We Wanted

Allergan's Results Were Exactly the Soft Catalyst We Wanted

The company hit all the major points of investor concern.

Get Beyond Biotech and Israeli Stocks are a Screaming Buy

Get Beyond Biotech and Israeli Stocks are a Screaming Buy

The worldwide selloff in biotech stocks and the lack of performance by generic drug giant Teva has hampered Israeli stocks thus far in 2016.

Biotech Gets a Lifeline

Biotech Gets a Lifeline

Solid earnings and the start of some M&A activity may be just what this sector needs to rise.

Teva's Charts Show Declining Health

Teva's Charts Show Declining Health

If TEVA breaks below $50, then a longer-term decline could be in the cards.

Sohn Preview: Dan Ariely, Zach Schreiber, Adam Fisher Headline Speakers

Sohn Preview: Dan Ariely, Zach Schreiber, Adam Fisher Headline Speakers

This year's mix of Sohn speakers includes asset managers, a behavioral economist and two-time Super Bowl champ Eli Manning.

2 Small-Cap Biotechs With Big Ambitions

2 Small-Cap Biotechs With Big Ambitions

Inovio Pharmaceuticals and Eagle Pharmaceuticals both boast solid pipelines and sound balance sheets.